107623-21-2

Usage

Uses

Used in Pharmaceutical Industry:
1-Benzyloxy-3-iodobenzene is used as a building block for the synthesis of various organic compounds, particularly in the development of pharmaceuticals. Its unique structure allows for the creation of new chemical entities with potential therapeutic applications.
Used in Agrochemical Industry:
Similarly, in the agrochemical sector, 1-benzyloxy-3-iodobenzene serves as a key intermediate in the synthesis of compounds designed for agricultural applications, such as pesticides and herbicides, leveraging its reactivity in organic synthesis processes.
Used in Research Laboratories:
1-Benzyloxy-3-iodobenzene is also utilized in research settings for the exploration and development of novel chemical compounds and materials. Its potential for substitution reactions facilitates innovative approaches in chemical research.
Used in Medicinal Chemistry and Drug Discovery:
Due to its potential biological activity, 1-benzyloxy-3-iodobenzene is a subject of interest in medicinal chemistry and drug discovery. It may contribute to the design of new drugs by providing a structural foundation that can be modified to target specific biological pathways or receptors.

InChI:InChI=1/C13H11IO/c14-12-7-4-8-13(9-12)15-10-11-5-2-1-3-6-11/h1-9H,10H2

Upstream product

• 626-02-8 3-Iodophenol 
• 100-44-7 benzyl chloride 
• 645-00-1 m-iodonitrobenzene 
• 100-51-6 benzyl alcohol 
• 100-39-0 benzyl bromide 
• 61535-46-4 3-benzyloxy-benzoyl chloride 

Downstream Products

• 132470-28-1 3'-Benzyloxy-4-methoxybiphenyl 
• 220284-70-8 1-(3-Benzyloxy-phenyl)-4-(3-cyclopentyloxy-4-methoxy-phenyl)-pyrrolidin-2-one 
• 585509-90-6 1-Benzyloxy-3-(4-tert-butyl-cyclohexyloxy)-benzene 
• 585509-91-7 1-Benzyloxy-3-(4-tert-butyl-cyclohexyloxy)-benzene 
• 585509-92-8 1-Benzyloxy-3-phenoxy-benzene 
• 889129-34-4 N-(3-benzyloxyphenyl)pyrrolidin-2-one 
• 889129-39-9 1-(3-benzyloxy-phenyl)-azepan-2-one 
• 220284-92-4 4-(3-Cyclopentyloxy-4-methoxy-phenyl)-1-(3-hydroxy-phenyl)-pyrrolidin-2-one 
• 122294-02-4 methyl 3'-(benzyloxy)-[1,1'-biphenyl]-4-carboxylate 
• 626-02-8 3-Iodophenol 
• 1192064-42-8 1-[3-(benzyloxy)phenyl]-1H-1,2,4-triazole 
• 1160113-96-1 2-(3-(3-(benzyloxy)phenyl)but-3-enyl)isoindoline-1,3-dione 
• 24318-00-1 3-(benzyloxy)nitrobenzol 
• 946-80-5 (benzyloxy)benzene 

Relevant academic research and scientific papers

Total Synthesis of Cochlearol B via Intramolecular [2+2] Photocycloaddition

Herein, we describe the first total synthesis of cochlearol B, a meroterpenoid natural product featuring a 4/5/6/6/6-fused pentacyclic structure. Key steps, oxidative cyclization and subsequent intramolecular [2+2] photocycloaddition, which constructed the pentacyclic structure in highly stereoselective manner, allowed efficient access to cochlearol B with the longest linear sequence of 16 steps, and in 9 % overall yield. Single-crystal X-ray crystallographic analysis clearly confirmed the stereochemistry of cochlearol B.

Hydrogen-Bond-Donor Solvents Enable Catalyst-Free (Radio)-Halogenation and Deuteration of Organoborons

A hydrogen bond donor solvent assisted (radio)halogenation and deuteration of organoborons has been developed. The reactions exhibited high functional group tolerance and needed only an ambient atmosphere. Most importantly, compared to literature methods, our conditions are more consistent with the principals of green chemistry (e.g., metal-free, strong oxidant-free, more straightforward conditions).

Metathesis-active ligands enable a catalytic functional group metathesis between aroyl chlorides and aryl iodides

Current methods for functional group interconversion have, for the most part, relied on relatively strong driving forces which often require highly reactive reagents to generate irreversibly a desired product in high yield and selectivity. These approaches generally prevent the use of the same catalytic strategy to perform the reverse reaction. Here we describe a catalytic functional group metathesis approach to interconvert, under CO-free conditions, two synthetically important classes of electrophiles that are often employed in the preparation of pharmaceuticals and agrochemicals—aroyl chlorides (ArCOCl) and aryl iodides (ArI). Our reaction design relies on the implementation of a key reversible ligand C–P bond cleavage event, which enables a non-innocent, metathesis-active phosphine ligand to mediate a rapid aryl group transfer between the two different electrophiles. Beyond enabling a practical and safer approach to the interconversion of ArCOCl and ArI, this type of ligand non-innocence provides a blueprint for the development of a broad range of functional group metathesis reactions employing synthetically relevant aryl electrophiles.

BIARYL DERIVATIVE AS GPR120 AGONIST

The present invention relates to a biaryl derivative expressed by the chemical formula 1, a method for producing the biaryl derivative, a pharmaceutical composition comprising same, and use of same, the biaryl derivative expressed by the chemical formula 1, as a GPR120 agonist, promoting GLP-1 generation in the gastro-intestinal tract, reducing insulin resistance in the liver, muscles and the like from anti-inflammatory activity in the macrophage, pancreatic cells and the like, and allowing effective use in prevention or treatment of inflammation or metabolic diseases such as diabetes, complications from diabetes, obesity, non-alcoholic fatty liver disease, fatty liver disease, and osteoporosis.

Palladium-Catalyzed Synthesis of Pyrayaquinones, Murrayaquinones, and Murrayafoline-B

We describe the total synthesis of murrayafoline-B and seven carbazole-1,4-quinone alkaloids. A palladium(II)-catalyzed oxidative cyclization is used to construct the carbazole skeleton. Pyran annulation and oxidation provide pyrayaquinone-A, -B, and -C. DIBAL-H-promoted reductive ring opening of pyrano[3,2-a]carbazole precursors leads to the prenylated and geranylated carbazole-1,4-quinone alkaloids murrayaquinone-B, -C, -D, and -E and to murrayafoline-B.

The first total synthesis of glycyrol

We report the first total synthesis of glycyrol. Glycyrol, isolated from Glycyrrhizae Radix, has a unique skeleton of a benzofuran coumarin. The key steps are Smiles rearrangement and selective introduction of prenyl and O-methyl groups. The first application of a novel precursor for Smiles rearrangement, 3-benzyloxy-substituted (diacetoxyiodo)benzene, showed the synthetic possibility for diverse precursors. The introduction of a benzyl protecting group was important because selective deprotection was hard due to the low solubility of intermediates.

NOVEL HETEROCYCLIC AMIDE DERIVATIVES HAVING DIHYDROOROTATE DEHYDROGENASE INHIBITING ACTIVITY

Novel heterocyclic amide derivatives having pharmacological effects, that is, compounds represented by the general formula (1) or salts thereof: (1) wherein X1-X2 is S-CH2 or the like; R1 is alkyl or the like; p is 0 to 7; R2 is hydrogen, alkyl, or the like; R3 is hydrogen, alkyl, or the like; Y1-Y2 is CH=CH or the like; R4 is halogeno, alkyl, or the like; q is 0 to 4; and R5 is halogeno, hydrogen, alkyl, or the like.

Synthesis of a new family of N-aryl lactams active on chemesthesis and taste

A new class of synthetic compounds with chemesthetic activity has been identified. They have been designed ex-novo by structural similarity with known cooling compounds such as menthol, icilin and cyclic ketoenamines. 19 new derivatives have been obtained

NOVEL CRYSTALLINE FORMS OF ANTIDIABETIC COMPOUNDS

Novel crystalline forms of two indole compounds connected to phenoxyalkylcarboxylic acid groups are selective PPAR gamma partial agonists that are useful in the treatment of type 2 diabetes, hyperglycemia, obesity, dyslipidemia, and the metabolic syndrome. The novel crystal forms include a crystalline free acid dihydrate and crystalline free acid anhydrate of one compound and several crystalline forms of the free acid and the sodium salt of the second compound. The invention also relates to pharmaceutical compositions comprising these novel crystal forms, processes to prepare the crystal forms and their pharmaceutical compositions, and uses of the crystal forms in the treatment of type 2 diabetes and other PPAR gamma modulated diseases.

BICYCLIC DERIVATIVES AS PPAR MODULATORS

The present invention is directed to compounds represented by the following structural formula, Formula (I), and stereoisomers, pharmaceutically acceptable salts, solvates and hydrates thereof, wherein: (a) R2 is selected from the group consisting of C0-C8 alkyl and C1-4- heteroalkyl; (b) X is selected from the group consisting of a single bond, O, S, S(O)2 and N; (c) U is an aliphatic linker wherein one carbon atom of the aliphatic linker is optionally replaced with O, NH or S, and wherein such aliphatic linker is optionally substituted with from one to four substituents each independently selected from R30; (d) Y is selected from the group consisting of C, O, S, NH and a single bond; and (e) E is C(R3)(R4)A or A.